Browse ULBP3

Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor
Domain PF00129 Class I Histocompatibility antigen
Function

Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity.

> Gene Ontology
 
Biological Process GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0019882 antigen processing and presentation
GO:0030101 natural killer cell activation
GO:0042267 natural killer cell mediated cytotoxicity
Molecular Function GO:0003823 antigen binding
GO:0046703 natural killer cell lectin-like receptor binding
Cellular Component GO:0031225 anchored component of membrane
GO:0046658 anchored component of plasma membrane
> KEGG and Reactome Pathway
 
KEGG hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ULBP3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ULBP3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27116977GliomaPromote immunity (NK cell function)IDH mutant glioma cells acquire resistance to NK cells through epigenetic silencing of NKG2D ligands ULBP1 and ULBP3.
16621962LymphomaPromote immunity (T and NK cell function)ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. ULBPs are human ligands for NKG2D, an activating receptor expressed on natural killer (NK) cells, NK1.1(+) T cells, and T cells. We report that ectopic expression of ULBP1 or ULBP2 on murine EL4 or RMA tumor cells elicits potent antitumor responses in syngeneic C57BL/6 and SCID mice. Although binding of ULBP3 to murine NKG2D could not be demonstrated in vitro, ULBP3 can also stimulate antitumor responses, suggesting that ULBP3 binds to murine NKG2D or possibly another receptor in vivo. IL-15 was found to strongly enhance the immune response directed against ULBP-expressing tumors.
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ULBP3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ULBP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1460.637
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4040.442
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0460.919
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1150.891
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6840.594
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1280.431
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8080.113
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8820.227
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9850.24
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5390.497
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.370.729
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1450.334
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ULBP3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ULBP3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ULBP3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ULBP3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ULBP3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ULBP3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolULBP3
NameUL16 binding protein 3
Aliases RAET1N; ALCAN-gamma; N2DL-3; NKG2DL3; UL16-binding protein 3; retinoic acid early transcript 1N; NKG2D ligan ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ULBP3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.